Anzeige
Mehr »
Dienstag, 21.07.2026 - Börsentäglich über 12.000 News
42 Proben im Labor - Jetzt beginnt die spannendste Phase für diese Wolfram-Aktie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
13.07.Insilico's Chinese partner returns for $177M pact to explore 'mass market' CNS indication
10.07.GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its 'priority asset'
10.07.Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail
09.07.Roche ends 2 Huntington's disease programs, including Ionis-partnered tominersen
09.07.Fate's off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease
09.07.GSK cuts losses on $700M upfront Alzheimer's collab with Alector following 2 clinical failures
08.07.Prime wins patent fight with Beam to continue work on AATD gene editing therapy
08.07.Satellos' 'intriguing' Duchenne data raise hopes ahead of key readout
08.07.Scipher picks up Chemomab's rheumatoid arthritis drug, Nasdaq listing in all-stock merger
08.07.AstraZeneca pens $2.1B Sino deal for challenger to Merck's COPD drug Ohtuvayre
07.07.MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization
07.07.Whitehawk swoops in for five ADCs via development deal with China's Biocytogen
07.07.Boehringer bags PVT's viral vector platform for cancer vaccine R&D
07.07.As US lawmakers increase scrutiny of Chinese trials, industry fears 'huge distraction and expense'
07.07.Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s
07.07.Kailera's oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials
06.07.Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline
03.07.United Therapeutics pays $140M for thymic cell therapy startup
03.07.AstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPC
02.07.Fosun pays $32M to join Lilly and Novartis in fiercely competitive psoriasis market
02.07.Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS
01.07.Merck halts ph. 2 Alzheimer's trial after Neuphoria small molecule underwhelms
01.07.Ipsen gets the Memo, penning €700M deal to buy rare disease biotech for clinical-stage asset
01.07.Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer's asset in $2.2B deal
30.06.Bain-backed bone specialist Angitia drops lead spinal fusion candidate